/

Società

As

Non verificato

AstraZeneca

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

97 comunicati stampa

Guarda tutti i comunicati

09/03/2026

Mercato del lavoro

Industria

Scienza

Igiene alimentare

Medicina - Varie

Biotecnologia

Sanità

Farmaceutica

Salute

Oncologia

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer

Fonte

Emittente

1.00

0

20/02/2026

Biotecnologia

Igiene alimentare

Sanità

Salute

Farmaceutica

Oncologia

Scienza

Medicina - Varie

Industria

CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting

Fonte

Emittente

1.00

0

13/02/2026

Salute

Sanità

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Industria

Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine

Fonte

Emittente

1.00

0

11/02/2026

Biotecnologia

Farmaceutica

Sanità

Salute

Associazioni/Professionisti

Volontariato/Solidarietà/Non profit

AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US

Fonte

Emittente

1.00

0

10/02/2026

Biotecnologia

Farmaceutica

Salute

Web e Social Network

Telefonia e Varie

Mercato azionario

AstraZeneca results: FY and Q4 2025

Fonte

Emittente

1.00

0

03/02/2026

Industria

Scienza

Igiene alimentare

Medicina - Varie

Biotecnologia

Sanità

Farmaceutica

Salute

Oncologia

DATROWAY® (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy

Fonte

Emittente

1.00

0

02/02/2026

Biotecnologia

Sanità

Farmaceutica

Salute

Industria

AstraZeneca begins trading on the New York Stock Exchange

Fonte

Emittente

1.00

0

08/01/2026

Salute

Industria

Scienza

Farmaceutica

Biotecnologia

Mercato del lavoro

Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit

Fonte

Emittente

1.00

0

22/12/2025

Scienza

Igiene alimentare

Medicina - Varie

Biotecnologia

Salute

Farmaceutica

Sanità

Oncologia

Industria

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer

Fonte

Emittente

1.00

0

15/12/2025

Industria

Biotecnologia

Salute

Farmaceutica

Oncologia

Scienza

Vetrine/Shopping

Medicina - Varie

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0